• LAST PRICE
    119.6500
  • TODAY'S CHANGE (%)
    Trending Down-1.1100 (-0.9192%)
  • Bid / Lots
    119.4700/ 2
  • Ask / Lots
    119.8200/ 7
  • Open / Previous Close
    119.7300 / 120.7600
  • Day Range
    Low 118.7900
    High 121.8000
  • 52 Week Range
    Low 76.5301
    High 131.4900
  • Volume
    287,000
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Monday's close: 120.75
TimeVolumeBNTX
09:32 ET31274120.83
09:33 ET7774120.67
09:35 ET17805121.42
09:37 ET12764119.97
09:39 ET2543119.66
09:42 ET9310120.25
09:44 ET7611119.2612
09:46 ET3100119.1499
09:48 ET5081119.79
09:50 ET825119.83
09:51 ET4157119.315
09:53 ET650119.47
09:55 ET2789119.92
09:57 ET4027119.9
10:00 ET100119.705
10:02 ET4380120.185
10:04 ET8900120.54
10:06 ET16616121.085
10:08 ET18739121.11
10:09 ET6878121.11
10:11 ET2421120.79
10:13 ET1874120.84
10:15 ET5909120.6417
10:18 ET3553119.948
10:20 ET10876119.69
10:22 ET2000120.25
10:24 ET1954120.205
10:26 ET1076119.67
10:27 ET10072120.0725
10:29 ET2157119.635
10:31 ET2300119.855
10:33 ET1800119.7
10:36 ET1708119.46
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesBNTX
Biontech SE
27.1B
-58.3x
---
United StatesBGNE
Beigene Ltd
21.4B
-22.7x
---
United StatesINCY
Incyte Corp
13.8B
525.1x
+39.11%
United StatesCRL
Charles River Laboratories International Inc
10.0B
24.3x
+15.57%
United StatesUTHR
United Therapeutics Corp
16.6B
16.1x
+8.22%
United StatesARGX
argenx SE
36.6B
-718.8x
---
As of 2024-11-26

Company Information

BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.

Contact Information

Headquarters
An der Goldgrube 12MAINZ, Germany 55131
Phone
---
Fax
---

Executives

Independent Chairman of the Supervisory Board
Helmut Jeggle
Chief Executive Officer, Member of the Management Board
Ugur Sahin
Independent Deputy Chairman of the Supervisory Board
Ulrich Wandschneider
Chief Financial Officer
Jens Holstein
Chief Operating Officer, Member of the Management Board
Sierk Poetting

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$27.1B
Revenue (TTM)
$3.2B
Shares Outstanding
239.7M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.22
EPS
$-2.05
Book Value
$89.37
P/E Ratio
-58.3x
Price/Sales (TTM)
8.5
Price/Cash Flow (TTM)
---
Operating Margin
-30.81%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.